{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-018135","form_type":"8-K","ticker":"ORMP","cik":"0001176309","company_name":"ORAMED PHARMACEUTICALS INC.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.091812+00:00","generated_at":"2026-05-26T01:03:54.853339+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Oramed's RoyaltyVest signs exclusive Rest of World license for Scilex lidocaine products ZTlido/SP-103","bullets":["RoyaltyVest (50% owned by Oramed) obtains exclusive license to develop, manufacture and commercialize ZTlido (lidocaine 1.8%) and SP-103 outside the U.S.","Revenue share: RoyaltyVest and Scilex Pharma each receive 50% of Net Revenue, paid quarterly by RoyaltyVest.","Licensee must commit $200,000 annually (or in-kind) and obtain regulatory approval in at least one Major Market Country within 18 months of effective date.","Scilex Holding Company guaranteed Scilex Pharma's obligations under the license via a parent guarantee; guarantee terminates upon a change of control.","Oramed transferred 50% of RoyaltyVest shares to Oramed; Oramed controls half of RoyaltyVest's board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-018135","json":"https://secwatch.observer/filing/0001213900-25-018135.json","markdown":"https://secwatch.observer/filing/0001213900-25-018135.md","text":"https://secwatch.observer/filing/0001213900-25-018135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025018135/0001213900-25-018135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1176309/000121390025018135/ea0232360-8k_oramed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:03:54.853339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}